icon/medical
icon/medical

The Putnam Medical & Scientific Affairs team brings together deep scientific expertise and rigorous problem-solving ability to support medical teams in their decision making and planning. Our projects seek to help teams deliver on the clinical value of the product/franchise and optimize the ability to bring the benefits to the appropriate patients. Key examples of how our team supports a broad range of client includes:

  • Global medical plan development and dissemination/adaptation to individual countries
  • Need based Evidence Generation Planning
  • Clinical Development and Lifecycle Strategy
  • Strategic Expert Stakeholder Engagement (to seek feedback and guidance)

Supporting our Medical & Scientific Affairs Strategy is Functional Expertise in Key Disciplines

Clinical & Scientific Expertise

Understanding and identifying the EVIDENCE with meticulous literature reviews

Deep Experience & Rigorous Strategic Perspective

Drawing on Deep Expertise and Framing Issues from a STRATEGIC PERSPECTIVE to produce client impact

Clinical Outcomes Simulation Modeling

Quantifying the IMPACT on patient outcomes

Projects

  • Environmental assessment (disease, treatment flows, stakeholders)
  • Literature review and evidence gap identification
  • Comprehensive disease narrative
  • Indication and/or endpoint prioritization
  • Registrational pathway evaluation
  • National advisory committee evaluation
  • Lifecycle planning
  • Needs-driven global and country evidence generation strategies
  • Clinical trial characterization
  • Strategic stakeholder identification and mapping
  • Stakeholder engagement strategy and planning
  • Publication plan
  • Advisory board, publication support

Get in Touch

We partner with clients to address the most complex challenges facing the life sciences industry. Our carefully designed evidence-based strategies allow us to generate winning insights for our clients all over the globe.

How can we help you and your team?
  • This field is for validation purposes and should be left unchanged.

Strategy for the Life Sciences